Published in Nat Rev Rheumatol on October 01, 2009
Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin-6 and granulocyte macrophage colony-stimulating factor. J Infect Dis (2011) 2.69
Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol (2009) 1.95
Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling. Circ Res (2014) 1.51
Chikungunya disease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia. PLoS Negl Trop Dis (2012) 1.42
Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis (2012) 1.17
Managing macrophages in rheumatoid arthritis by reform or removal. Curr Rheumatol Rep (2012) 1.17
Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy. J Interferon Cytokine Res (2015) 1.09
GM-CSF: An immune modulatory cytokine that can suppress autoimmunity. Cytokine (2015) 1.09
TLR1/2, TLR7, and TLR9 signals directly activate human peripheral blood naive and memory B cell subsets to produce cytokines, chemokines, and hematopoietic growth factors. J Clin Immunol (2010) 1.09
Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms. PLoS One (2013) 1.01
Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol (2015) 0.97
Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm (2015) 0.93
T cell expression of granulocyte-macrophage colony-stimulating factor in juvenile arthritis is contingent upon Th17 plasticity. Arthritis Rheumatol (2014) 0.89
The adaptor protein CIKS/ACT1 is necessary for collagen-induced arthritis, and it contributes to the production of collagen-specific antibody. Arthritis Rheum (2010) 0.89
Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis. Ann Rheum Dis (2014) 0.88
Role of TH-17 cells in rheumatic and other autoimmune diseases. Rheumatology (Sunnyvale) (2011) 0.86
Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford) (2016) 0.86
Hematopoietic colony-stimulating factors: new players in tumor-nerve interactions. J Mol Med (Berl) (2010) 0.84
The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis. IUBMB Life (2010) 0.83
DRB1*0402 may influence arthritis by promoting naive CD4+ T-cell differentiation in to regulatory T cells. Eur J Immunol (2014) 0.83
Chikungunya fever: focus on peripheral markers of pathogenesis. J Infect Dis (2011) 0.80
Aciculatin inhibits granulocyte colony-stimulating factor production by human interleukin 1β-stimulated fibroblast-like synoviocytes. PLoS One (2012) 0.79
Transcriptional mechanisms underlying sensitization of peripheral sensory neurons by granulocyte-/granulocyte-macrophage colony stimulating factors. Mol Pain (2013) 0.78
IL-1 Coordinates the Neutrophil Response to C. albicans in the Oral Mucosa. PLoS Pathog (2016) 0.78
The macrophages in rheumatic diseases. J Inflamm Res (2016) 0.78
Replacements of rare herbs and simplifications of traditional chinese medicine formulae based on attribute similarities and pathway enrichment analysis. Evid Based Complement Alternat Med (2013) 0.77
G-CSF maintains controlled neutrophil mobilization during acute inflammation by negatively regulating CXCR2 signaling. J Exp Med (2016) 0.77
Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res (2014) 0.77
Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nat Rev Drug Discov (2016) 0.77
Complementary and alternative medicine in reducing radiation-induced skin toxicity. Radiat Environ Biophys (2014) 0.76
Successes, challenges and developments in Australian rheumatology. Nat Rev Rheumatol (2015) 0.76
GM-CSF primes cardiac inflammation in a mouse model of Kawasaki disease. J Exp Med (2016) 0.76
Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF(+) T Lymphocytes. Clin Rev Allergy Immunol (2017) 0.75
Molecular basis of in vitro affinity maturation and functional evolution of a neutralizing anti-human GM-CSF antibody. MAbs (2015) 0.75
Rheumatoid Arthritis Was Negatively Associated with Alzheimer's Disease: A Population-Based Case-Control Study. PLoS One (2016) 0.75
Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines. Hum Vaccin Immunother (2016) 0.75
Thrombin stimulates synthesis of macrophage colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor by human proximal tubular epithelial cells in culture. Nephron Extra (2012) 0.75
Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. Drug Des Devel Ther (2017) 0.75
Acetylation impacts Fli-1-driven regulation of granulocyte colony stimulating factor. Eur J Immunol (2016) 0.75
Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother (2014) 0.75
Growth factors and IL-17 in hereditary angioedema. Clin Exp Med (2015) 0.75
Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest (1998) 13.05
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity (2002) 9.29
Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med (1966) 7.30
Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity (2005) 6.71
Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol (2008) 5.86
GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med (2007) 4.94
Pulmonary alveolar proteinosis. N Engl J Med (2003) 4.93
Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science (1994) 4.81
New therapies for treatment of rheumatoid arthritis. Lancet (2007) 4.80
Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor. EMBO J (1989) 4.54
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res (2001) 4.49
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A (1994) 4.19
Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest (2008) 3.90
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet (2009) 3.55
Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature (2009) 3.25
Impaired production and increased apoptosis of neutrophils in granulocyte colony-stimulating factor receptor-deficient mice. Immunity (1996) 2.95
Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. J Immunol (2000) 2.81
Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects. Blood (2009) 2.79
G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med (2003) 2.31
Rheumatoid arthritis: opposing actions of haemopoietic growth factors and slow-acting anti-rheumatic drugs. Lancet (1993) 2.00
GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J Exp Med (2008) 1.99
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther (2009) 1.98
SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest (2006) 1.92
Granulocyte colony-stimulating factor and neutrophils--forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol (2006) 1.85
Homeostatic regulation of blood neutrophil counts. J Immunol (2008) 1.81
Neutrophil kinetics in man. J Clin Invest (1976) 1.72
Levels of serum granulocyte colony-stimulating factor in patients with infections. Blood (1990) 1.71
Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res (2001) 1.66
Macrophage phagocytosis of apoptotic neutrophils is critically regulated by the opposing actions of pro-inflammatory and anti-inflammatory agents: key role for TNF-alpha. FASEB J (2008) 1.60
Treatment with anti-granulocyte antibodies inhibits the effector phase of experimental autoimmune encephalomyelitis. J Immunol (1998) 1.60
Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol (1992) 1.59
The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum (2009) 1.59
"Emergency" granulopoiesis in G-CSF-deficient mice in response to Candida albicans infection. Blood (2000) 1.59
G-CSF: a key regulator of neutrophil production, but that's not all! Growth Factors (2005) 1.57
Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest (2001) 1.40
IL-23 is required for neutrophil homeostasis in normal and neutrophilic mice. J Immunol (2007) 1.35
A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. Blood (2008) 1.34
IL-17A controls IL-17F production and maintains blood neutrophil counts in mice. J Immunol (2009) 1.25
Microbial antigen triggers rapid mobilization of TNF-alpha to the surface of mouse neutrophils transforming them into inducers of high-level dendritic cell TNF-alpha production. J Immunol (2005) 1.24
Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis Rheum (2004) 1.22
Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proc Natl Acad Sci U S A (2004) 1.18
High serum and synovial fluid granulocyte colony stimulating factor (G-CSF) concentrations in patients with rheumatoid arthritis. Clin Exp Rheumatol (2001) 1.06
Effects of recombinant human granulocyte colony-stimulating factor administration on neutrophil phenotype and functions. Haematologica (1998) 1.02
Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model. Ann Rheum Dis (2008) 1.00
Age-related impairment of GM-CSF-induced signalling in neutrophils: role of SHP-1 and SOCS proteins. Ageing Res Rev (2006) 1.00
Polymorphonuclear granulocytes at the pannus-cartilage junction in rheumatoid arthritis. Arthritis Rheum (1980) 0.97
GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis (2006) 0.96
The detection and initial characterization of colony-stimulating factors in synovial fluid. Clin Exp Immunol (1988) 0.89
Enhanced neutrophilic granulopoiesis in rheumatoid arthritis. Involvement of neutrophils in disease progression. J Rheumatol (2000) 0.84
Treatment-induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis. Intern Med J (2008) 0.83
T lymphocytes from granulocyte colony-stimulating factor-/- mice produce large quantities of interferon-gamma in a chronic infection model. Immunology (2000) 0.81
Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant (1997) 0.80
Perpetuation of inflammation associated with experimental arthritis: the role of macrophage activation by neutrophilic myeloperoxidase. Mediators Inflamm (1998) 0.79
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol (2007) 12.76
Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J Exp Med (2006) 7.76
IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med (2006) 5.76
Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity (2006) 5.40
IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev (2004) 4.78
ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature (2005) 4.24
The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement. Blood (2008) 2.83
Dysregulated hematopoietic stem and progenitor cell activity promotes interleukin-23-driven chronic intestinal inflammation. Immunity (2012) 2.72
Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1. Immunity (2007) 2.61
Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A (2008) 2.57
Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med (2009) 2.41
SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest (2006) 1.92
Granulocyte colony-stimulating factor and neutrophils--forgotten mediators of inflammatory disease. Nat Clin Pract Rheumatol (2006) 1.85
Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell (2013) 1.67
Different cross-presentation pathways in steady-state and inflammatory dendritic cells. Proc Natl Acad Sci U S A (2009) 1.46
Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. Arthritis Rheum (2006) 1.42
Severely compromised quality of life in women and those of lower socioeconomic status waiting for joint replacement surgery. Arthritis Rheum (2005) 1.41
A key role for G-CSF-induced neutrophil production and trafficking during inflammatory arthritis. Blood (2008) 1.34
Mutations in the cofilin partner Aip1/Wdr1 cause autoinflammatory disease and macrothrombocytopenia. Blood (2007) 1.30
Antigen delivery via two molecules on the CD8- dendritic cell subset induces humoral immunity in the absence of conventional "danger". Eur J Immunol (2005) 1.23
The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover. Arthritis Rheum (2003) 1.21
Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J Clin Invest (2003) 1.18
Critical role for granulocyte colony-stimulating factor in inflammatory arthritis. Proc Natl Acad Sci U S A (2004) 1.18
The mouse mast cell-restricted tetramer-forming tryptases mouse mast cell protease 6 and mouse mast cell protease 7 are critical mediators in inflammatory arthritis. Arthritis Rheum (2008) 1.14
The SOCS box of suppressor of cytokine signaling-3 contributes to the control of G-CSF responsiveness in vivo. Blood (2007) 1.13
ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. Arthritis Rheum (2005) 1.09
Development of spontaneous multisystem autoimmune disease and hypersensitivity to antibody-induced inflammation in Fcgamma receptor IIa-transgenic mice. Arthritis Rheum (2005) 1.08
GM-CSF as a therapeutic target in inflammatory diseases. Mol Immunol (2013) 1.07
GM-CSF increases cross-presentation and CD103 expression by mouse CD8⁺ spleen dendritic cells. Eur J Immunol (2011) 1.07
Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med (2012) 1.07
Differentiation of inflammatory dendritic cells is mediated by NF-κB1-dependent GM-CSF production in CD4 T cells. J Immunol (2011) 1.06
Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. EMBO Rep (2010) 1.05
Promotion of the local differentiation of murine Th17 cells by synovial macrophages during acute inflammatory arthritis. Arthritis Rheum (2008) 1.05
Patient education and self-management programs in arthritis. Med J Aust (2004) 1.01
Defects in the Bcl-2-regulated apoptotic pathway lead to preferential increase of CD25 low Foxp3+ anergic CD4+ T cells. J Immunol (2011) 1.01
Endogenous IL-11 is pro-inflammatory in acute methylated bovine serum albumin/interleukin-1-induced (mBSA/IL-1)arthritis. Cytokine (2005) 0.98
Acute CD4+ T lymphocyte-dependent interleukin-1-driven arthritis selectively requires interleukin-2 and interleukin-4, joint macrophages, granulocyte-macrophage colony-stimulating factor, interleukin-6, and leukemia inhibitory factor. Arthritis Rheum (2005) 0.95
Prevalence of coronary heart disease and cardiovascular risk factors in a national cross-sectional cohort study of systemic sclerosis. Ann Rheum Dis (2012) 0.92
Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease. Clin Transl Gastroenterol (2012) 0.92
Prevalence and cost of musculoskeletal disorders: a population-based, public hospital system healthcare consumption approach. J Rheumatol (2007) 0.91
An ethyl-nitrosourea-induced point mutation in phex causes exon skipping, x-linked hypophosphatemia, and rickets. Am J Pathol (2002) 0.91
Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am J Pathol (2002) 0.91
Rheumatoid arthritis patients receive less frequent acute reperfusion and secondary prevention therapy after myocardial infarction compared with the general population. Arthritis Res Ther (2010) 0.91
Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. Immunol Cell Biol (2003) 0.89
Bcl-2 antagonists kill plasmacytoid dendritic cells from lupus-prone mice and dampen interferon-α production. Arthritis Rheumatol (2015) 0.86
Anti-citrullinated peptide antibody: death of the rheumatoid factor? Med J Aust (2009) 0.84
Reducing the cardiovascular disease burden in rheumatoid arthritis. Med J Aust (2006) 0.83
Autoimmune regulator controls T cell help for pathogenetic autoantibody production in collagen-induced arthritis. Arthritis Rheum (2009) 0.83
Rapid specific amplification of rat antibody cDNA from nine hybridomas in the presence of myeloma light chains. J Immunol Methods (2006) 0.82
Retinal vascular calibre is altered in patients with rheumatoid arthritis: a biomarker of disease activity and cardiovascular risk? Rheumatology (Oxford) (2010) 0.82
Bcl-2 overexpression ameliorates immune complex-mediated arthritis by altering FcγRIIb expression and monocyte homeostasis. J Leukoc Biol (2013) 0.82
Cardiovascular disease in systemic sclerosis--an emerging association? Arthritis Res Ther (2011) 0.82
Anti-CD45RB antibody deters xenograft rejection by modulating T cell priming and homing. Int Immunol (2002) 0.81
Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis. J Leukoc Biol (2011) 0.79
Key role of suppressor of cytokine signaling 3 in regulating gp130 cytokine-induced signaling and limiting chondrocyte responses during murine inflammatory arthritis. Arthritis Rheumatol (2014) 0.78
Sustained remission, possibly cure, of seronegative arthritis after high-dose chemotherapy and syngeneic hematopoietic stem cell transplantation. Arthritis Rheum (2005) 0.76
Experienced physiotherapists as gatekeepers to hospital orthopaedic outpatient care. Comment. Med J Aust (2008) 0.75